DGM

Overview

DGM is an inhibitor of the TGF-β1/Smad signaling pathway with significant antifibrotic effects. DGM inhibits the epithelial-mesenchymal transition (EMT) process in alveolar epithelial cells and slows the progression of pulmonary fibrosis in vivo by reducing lung inflammation, improving lung function, and decreasing extracellular matrix (ECM) remodeling. DGM can be used in research on idiopathic pulmonary fibrosis (IPF) and EMT-related diseases.

Application

Products | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > TGF-beta/Smad

Product Information

• Catalog No.: HY-W005379
• CAS No.: 162401-62-9
• Molecular Formula: C12H12F2O4
• Molecular Weight: 258.22
• Purity: 99.99%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (19.36 mM); Clear solution
• Availability: In-stock

Source

Original product source